Publicaciones en las que colabora con JULIO EDUARDO NUÑEZ VILLOTA (288)

2024

  1. Carbohydrate antigen 125-guided pre-TAVI medical optimization: impact on quality of life and clinical outcomes

    Revista Espanola de Cardiologia

  2. Combining loop with thiazide diuretics in patients discharged home after a heart failure decompensation: Association with 30-day outcomes

    European Journal of Internal Medicine

  3. Differential sex-related effect of left ventricular ejection fraction trajectory on the risk of mortality and heart failure readmission following hospitalization for acute heart failure: A longitudinal study

    European Journal of Heart Failure

  4. Effect of paced heart rate on quality of life and natriuretic peptides for stage B or C heart failure with preserved ejection fraction: A secondary analysis of the myPACE trial

    European Journal of Heart Failure, Vol. 26, Núm. 1, pp. 167-176

  5. Exercise training response according to baseline ferrokinetics in heart failure with preserved ejection fraction: A substudy of the TRAINING-HF trial

    Journal of Cachexia, Sarcopenia and Muscle, Vol. 15, Núm. 2, pp. 681-689

  6. Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

    Diagnostics, Vol. 14, Núm. 4

  7. Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial

    ESC Heart Failure, Vol. 11, Núm. 2, pp. 1258-1262

  8. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial

    JAMA network open, Vol. 7, Núm. 3, pp. e240809

  9. Noncardiovascular morbidity and mortality across left ventricular ejection fraction categories following hospitalization for heart failure

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 206-214

  10. β-Blocker Withdrawal and Functional Capacity Improvement in Patients with Heart Failure with Preserved Ejection Fraction

    JAMA Cardiology, Vol. 9, Núm. 4, pp. 392-396

2023

  1. An update on utilising brain natriuretic peptide for risk stratification, monitoring and guiding therapy in heart failure

    Expert Review of Molecular Diagnostics, Vol. 23, Núm. 6, pp. 521-533

  2. Chronotropic index and long-term outcomes in heart failure with preserved ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 7, pp. 511-518

  3. Clinical Predictors and Prognosis of Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) without ST-Segment Elevation in Older Adults

    Journal of Clinical Medicine, Vol. 12, Núm. 3

  4. Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction

    Scientific Reports, Vol. 13, Núm. 1

  5. Early glomerular filtration rate decline is associated with hemoglobin rise following dapagliflozin initiation in heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 76, Núm. 10, pp. 783-792

  6. Early glomerular filtration rates changes and risk of mortality in acute heart failure. The modifying role of admission renal function and decongestion

    European Journal of Internal Medicine, Vol. 115, pp. 96-103

  7. Eficacia de la realidad virtual en la reducción de la ansiedad en la revascularización de las OTC: diseño del ensayo ReViCTO

    REC: Interventional Cardiology, Vol. 5, Núm. 3, pp. 203-209

  8. Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome

    ESC Heart Failure, Vol. 10, Núm. 1, pp. 264-273

  9. Role of plasma carbohydrate antigen 125 to identify nonfrail patients in HF

    REC: CardioClinics, Vol. 58, Núm. 3, pp. 172-179

  10. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622